Cited by 845

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma

Open access

Steele, Colin W., Karim, Saadia A., Leach, Joshua D.G., Bailey, Peter, Upstill-Goddard, Rosanna, Rishi, Loveena, Foth, Mona, Bryson, Sheila, McDaid, Karen, Wilson, Zena, Eberlein, Catherine, Candido, Juliana B., Clarke, Mairi, Nixon, Colin, Connelly, John, Jamieson, Nigel, Carter, C. Ross, Balkwill, Frances, Chang, David K., Evans, T.R. Jeffry, Strathdee, Douglas, Biankin, Andrew V., Nibbs, Robert J.B., Barry, Simon T., Sansom, Owen J., Morton, Jennifer P.·2016·Cancer Cell

DOI 10.1016/j.ccell.2016.04.014

Open this paper in CoChat — free account

Abstract

CXCR2 has been suggested to have both tumor-promoting and tumor-suppressive properties. Here we show that CXCR2 signaling is upregulated in human pancreatic cancer, predominantly in neutrophil/myeloid-derived suppressor cells, but rarely in tumor cells. Genetic ablation or inhibition of CXCR2 abrogated metastasis, but only inhibition slowed tumorigenesis. Depletion of neutrophils/myeloid-derived suppressor cells also suppressed metastasis suggesting a key role for CXCR2 in establishing and maintaining the metastatic niche. Importantly, loss or inhibition of CXCR2 improved T cell entry, and combined inhibition of CXCR2 and PD1 in mice with established disease significantly extended survival. We show that CXCR2 signaling in the myeloid compartment can promote pancreatic tumorigenesis and is required for pancreatic cancer metastasis, making it an excellent therapeutic target.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2016.04.014

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer statistics, 2015
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,853
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621 · cited 2×
“Indeed, when we compare our mouse tumors with human tumors, we find that Cxcr2 deletion is associated with a switch away from the poorly prognostic squamous identity (Bailey et al., 2016).”
Self-citation
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
Colotta, F., Allavena, P., Sica, A., Garlanda, C., & Mantovani, A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp127 · Cited by 2,890
Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival
Özdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.005 · Cited by 2,681
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195
EMT and Dissemination Precede Pancreatic Tumor Formation
Rhim, A. D., Mirek, E. T., Aiello, N. M., Maitra, A., Bailey, J. M., McAllister, F., Reichert, M., Beatty, G. L., Rustgi, A. K., Vonderheide, R. H., et al. (2012) · Cell · doi:10.1016/j.cell.2011.11.025 · Cited by 2,136
Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., & Perucho, M. (1988) · Cell · doi:10.1016/0092-8674(88)90571-5 · Cited by 2,114
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100
Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network
Kuilman, T., Michaloglou, C., Vredeveld, L. C. W., Douma, S., van Doorn, R., Desmet, C. J., Aarden, L. A., Mooi, W. J., & Peeper, D. S. (2008) · Cell · doi:10.1016/j.cell.2008.03.039 · Cited by 2,086 · cited 1×
“For example, inflammatory signaling can promote oncogene-induced senescence (Acosta et al., 2008; Kuilman et al., 2008).”
Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., Dekleva, E. N., Saunders, T., Becerra, C. P., Tattersall, I. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.021 · Cited by 2,085
Chemokine signaling via the CXCR2 receptor reinforces senescence
Acosta, J. C., O'Loghlen, A., Banito, A., Guijarro, M. V., Augert, A., Raguz, S., Fumagalli, M., Da Costa, M., Brown, C., Popov, N., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.038 · Cited by 1,801 · cited 3×
“Of particular relevance to PDAC, are the elegant studies that show that CXCR2 reinforces RAS-mediated senescence in culture, and regulates the senescence-associated secretory phenotype (Acosta et al., 2008).”
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,672
Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice
Guerra, C., Schuhmacher, A. J., Cañamero, M., Grippo, P. J., Verdaguer, L., Pérez-Gallego, L., Dubus, P., Sandgren, E. P., & Barbacid, M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.01.012 · Cited by 1,224
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy
Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E., Cole, D. J., & Montero, A. J. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0523-4 · Cited by 1,215
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
Jacobetz, M. A., Chan, D. S., Neesse, A., Bapiro, T. E., Cook, N., Frese, K. K., Feig, C., Nakagawa, T., Caldwell, M. E., Zecchini, H. I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-302529 · Cited by 1,120
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis
Kim, S., Takahashi, H., Lin, W.-W., Descargues, P., Grivennikov, S., Kim, Y., Luo, J.-L., & Karin, M. (2009) · Nature · doi:10.1038/nature07623 · Cited by 1,100
A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis
Acharyya, S., Oskarsson, T., Vanharanta, S., Malladi, S., Kim, J., Morris, P. G., Manova-Todorova, K., Leversha, M., Hogg, N., Seshan, V. E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.042 · Cited by 1,085
Neutrophils support lung colonization of metastasis-initiating breast cancer cells
Wculek, S. K., & Malanchi, I. (2015) · Nature · doi:10.1038/nature16140 · Cited by 1,003
Dynamics of the immune reaction to pancreatic cancer from inception to invasion
Clark, C. E., Hingorani, S. R., Mick, R., Combs, C., Tuveson, D. A., & Vonderheide, R. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0175 · Cited by 990
Hereditary Pancreatitis and the Risk of Pancreatic Cancer
Lowenfels, A. B., Maisonneuve, P., DiMagno, E. P., Elitsur, Y., Gates, L. K., Perrault, J., Whitcomb, D. C., & International Hereditary Pancreatitis Study Group (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.6.442 · Cited by 988
Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer
Bayne, L. J., Beatty, G. L., Jhala, N., Clark, C. E., Rhim, A. D., Stanger, B. Z., & Vonderheide, R. H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.025 · Cited by 947 · cited 1×
“Recent studies have described the contribution of MDSCs to pancreatic cancer progression (Bayne et al., 2012), and the accumulation of MDSCs in patients with advanced pancreatic cancer correlates with disease stage (Diaz-Montero et al., 2009).”
Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote Metastasis
Yang, L., Huang, J., Ren, X., Gorska, A. E., Chytil, A., Aakre, M., Carbone, D. P., Matrisian, L. M., Richmond, A., Lin, P. C., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.004 · Cited by 918
Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs
Oskarsson, T., Acharyya, S., Zhang, X. H.-F., Vanharanta, S., Tavazoie, S. F., Morris, P. G., Downey, R. J., Manova-Todorova, K., Brogi, E., & Massagué, J. (2011) · Nature Medicine · doi:10.1038/nm.2379 · Cited by 869
Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer
Lesina, M., Kurkowski, M. U., Ludes, K., Rose-John, S., Treiber, M., Klöppel, G., Yoshimura, A., Reindl, W., Sipos, B., Akira, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.009 · Cited by 862
CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow
Eash, K. J., Greenbaum, A. M., Gopalan, P. K., & Link, D. C. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41649 · Cited by 791
Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
Highfill, S. L., Cui, Y., Giles, A. J., Smith, J. P., Zhang, H., Morse, E., Kaplan, R. N., & Mackall, C. L. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007974 · Cited by 767 · cited 1×
“CXCR2 also regulates the migration of myeloid-derived suppressor cells (MDSCs) (Highfill et al., 2014).”
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal
Fife, B. T., Pauken, K. E., Eagar, T. N., Obu, T., Wu, J., Tang, Q., Azuma, M., Krummel, M. F., & Bluestone, J. A. (2009) · Nature Immunology · doi:10.1038/ni.1790 · Cited by 759
Neutrophil and B Cell Expansion in Mice That Lack the Murine IL-8 Receptor Homolog
Cacalano, G., Lee, J., Kikly, K., Ryan, A. M., Pitts-Meek, S., Hultgren, B., Wood, W. I., & Moore, M. W. (1994) · Science · doi:10.1126/science.8036519 · Cited by 664
nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
Goldstein, D., El-Maraghi, R. H., Hammel, P., Heinemann, V., Kunzmann, V., Sastre, J., Scheithauer, W., Siena, S., Tabernero, J., Teixeira, L., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju413 · Cited by 658
The biology of myeloid‐derived suppressor cells: The blessing and the curse of morphological and functional heterogeneity
Youn, J., & Gabrilovich, D. I. (2010) · European Journal of Immunology · doi:10.1002/eji.201040895 · Cited by 568
Stat3 and MMP7 Contribute to Pancreatic Ductal Adenocarcinoma Initiation and Progression
Fukuda, A., Wang, S. C., Morris, J. P., Folias, A. E., Liou, A., Kim, G. E., Akira, S., Boucher, K. M., Firpo, M. A., Mulvihill, S. J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.002 · Cited by 521
KrasG12D-Induced IKK2/β/NF-κB Activation by IL-1α and p62 Feedforward Loops Is Required for Development of Pancreatic Ductal Adenocarcinoma
Ling, J., Kang, Y., Zhao, R., Xia, Q., Lee, D.-F., Chang, Z., Li, J., Peng, B., Fleming, J. B., Wang, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.006 · Cited by 513
Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma
Winograd, R., Byrne, K. T., Evans, R. A., Odorizzi, P. M., Meyer, A. R. L., Bajor, D. L., Clendenin, C., Stanger, B. Z., Furth, E. E., Wherry, E. J., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0215 · Cited by 459
STAT3 Plays a Critical Role in KRAS -Induced Pancreatic Tumorigenesis
Corcoran, R. B., Contino, G., Deshpande, V., Tzatsos, A., Conrad, C., Benes, C. H., Levy, D. E., Settleman, J., Engelman, J. A., & Bardeesy, N. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0908 · Cited by 413
Computational Modeling of Pancreatic Cancer Reveals Kinetics of Metastasis Suggesting Optimum Treatment Strategies
Haeno, H., Gonen, M., Davis, M. B., Herman, J. M., Iacobuzio-Donahue, C. A., & Michor, F. (2012) · Cell · doi:10.1016/j.cell.2011.11.060 · Cited by 409
Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis
Jamieson, T., Clarke, M., Steele, C. W., Samuel, M. S., Neumann, J., Jung, A., Huels, D., Olson, M. F., Das, S., Nibbs, R. J. B., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61067 · Cited by 391
Self-citation
Genetic progression in the pancreatic ducts
Hruban, R. H., Wilentz, R. E., & Kern, S. E. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65054-7 · Cited by 373
Gr-1+CD11b+ Myeloid Cells Tip the Balance of Immune Protection to Tumor Promotion in the Premetastatic Lung
Yan, H. H., Pickup, M., Pang, Y., Gorska, A. E., Li, Z., Chytil, A., Geng, Y., Gray, J. W., Moses, H. L., & Yang, L. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0706 · Cited by 372
Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity
Stromnes, I. M., Brockenbrough, J. S., Izeradjene, K., Carlson, M. A., Cuevas, C., Simmons, R. M., Greenberg, P. D., & Hingorani, S. R. (2014) · Gut · doi:10.1136/gutjnl-2013-306271 · Cited by 331
Transcriptional Response to Hypoxia in Human Tumors
Lal, A., Peters, H., St. Croix, B., Haroon, Z. A., Dewhirst, M. W., Strausberg, R. L., Kaanders, J. H. A. M., van der Kogel, A. J., & Riggins, G. J. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.17.1337 · Cited by 320
Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6Clow F4/80+ Extratumoral Macrophages
Beatty, G. L., Winograd, R., Evans, R. A., Long, K. B., Luque, S. L., Lee, J. W., Clendenin, C., Gladney, W. L., Knoblock, D. M., Guirnalda, P. D., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.010 · Cited by 293
CXCL8/IL‐8 and CXCL12/SDF‐1α co‐operatively promote invasiveness and angiogenesis in pancreatic cancer
Matsuo, Y., Ochi, N., Sawai, H., Yasuda, A., Takahashi, H., Funahashi, H., Takeyama, H., Tong, Z., & Guha, S. (2009) · International Journal of Cancer · doi:10.1002/ijc.24040 · Cited by 279
An NF-κB pathway–mediated positive feedback loop amplifies Ras activity to pathological levels in mice
Daniluk, J., Liu, Y., Deng, D., Chu, J., Huang, H., Gaiser, S., Cruz-Monserrate, Z., Wang, H., Ji, B., & Logsdon, C. D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59743 · Cited by 276
Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma
Ijichi, H., Chytil, A., Gorska, A. E., Aakre, M. E., Bierie, B., Tada, M., Mohri, D., Miyabayashi, K., Asaoka, Y., Maeda, S., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42754 · Cited by 256 · cited 3×
“…signaling pathways, such as STAT3/IL-6 (Baumgart et al., 2014; Corcoran et al., 2011; Fukuda et al., 2011; Lesina et al., 2011), NF-kB (Daniluk et al., 2012; Ling et al., 2012; Maniati et al., 2011), and CXCR2 (Ijichi et al., 2011; Matsuo et al., 2009a) have been implicated in PDAC progression.”
Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice
Maniati, E., Bossard, M., Cook, N., Candido, J. B., Emami-Shahri, N., Nedospasov, S. A., Balkwill, F. R., Tuveson, D. A., & Hagemann, T. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45797 · Cited by 248
Self-citation
T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma
Stromnes, I. M., Schmitt, T. M., Hulbert, A., Brockenbrough, J. S., Nguyen, H. N., Cuevas, C., Dotson, A. M., Tan, X., Hotes, J. L., Greenberg, P. D., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.022 · Cited by 200
Tumor-infiltrating neutrophils in pancreatic neoplasia
Reid, M. D., Basturk, O., Thirabanjasak, D., Hruban, R. H., Klimstra, D. S., Bagci, P., Altinel, D., & Adsay, V. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.113 · Cited by 177
Overexpression of CXCL5 Is Associated With Poor Survival in Patients With Pancreatic Cancer
Li, A., King, J., Moro, A., Sugi, M. D., Dawson, D. W., Kaplan, J., Li, G., Lu, X., Strieter, R. M., Burdick, M., et al. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2010.11.058 · Cited by 177
CXCR2 Expression in Tumor Cells Is a Poor Prognostic Factor and Promotes Invasion and Metastasis in Lung Adenocarcinoma
Saintigny, P., Massarelli, E., Lin, S., Ahn, Y.-H., Chen, Y., Goswami, S., Erez, B., O'Reilly, M. S., Liu, D., Lee, J. J., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-0263 · Cited by 166
Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas
Jamieson, N. B., Glen, P., McMillan, D. C., McKay, C. J., Foulis, A. K., Carter, R., & IMRIE, C. W. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602305 · Cited by 150
Self-citation
Dasatinib Inhibits the Development of Metastases in a Mouse Model of Pancreatic Ductal Adenocarcinoma
Morton, J. P., Karim, S. A., Graham, K., Timpson, P., Jamieson, N., Athineos, D., Doyle, B., McKay, C., Heung, M., Oien, K. A., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.03.034 · Cited by 148
Self-citation
CXC‐chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer
Matsuo, Y., Raimondo, M., Woodward, T. A., Wallace, M. B., Gill, K. R., Tong, Z., Burdick, M. D., Yang, Z., Strieter, R. M., Hoffman, R. M., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24383 · Cited by 140
Reversing systemic inflammatory response syndrome with chemokine receptor pepducins
Kaneider, N. C., Agarwal, A., Leger, A. J., & Kuliopulos, A. (2005) · Nature Medicine · doi:10.1038/nm1245 · Cited by 137
Inflammation-Induced NFATc1–STAT3 Transcription Complex Promotes Pancreatic Cancer Initiation by Kras G12D
Baumgart, S., Chen, N., Siveke, J. T., König, A. O., Zhang, J., Singh, S. K., Wolf, E., Bartkuhn, M., Esposito, I., Heßmann, E., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0593 · Cited by 123
Pharmacological Characterization of AZD5069, a Slowly Reversible CXC Chemokine Receptor 2 Antagonist
Nicholls, D., Wiley, K. E., Dainty, I. A., MacIntosh, F., Phillips, C., Gaw, A. J., & Mårdh, C. K. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.221358 · Cited by 95
CXCR2 inhibition suppresses acute and chronic pancreatic inflammation
Steele, C. W., Karim, S. A., Foth, M., Rishi, L., Leach, J. D. G., Porter, R. J., Nixon, C., Evans, T. J., Carter, C. R., Nibbs, R. J. B., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4555 · Cited by 75
Self-citation
Potential Targets for Pancreatic Cancer Immunotherapeutics
Dodson, L. F., Hawkins, W. G., & Goedegebuure, P. S. (2011) · Immunotherapy · doi:10.2217/imt.11.10 · Cited by 70
Oncogenic transcription factors: cornerstones of inflammation-linked pancreatic carcinogenesis
Baumgart, S., Ellenrieder, V., & Fernández-Zapico, M. E. (2011) · Gut · doi:10.1136/gutjnl-2011-301008 · Cited by 67
CXCR2 Macromolecular Complex in Pancreatic Cancer: A Potential Therapeutic Target in Tumor Growth
Wang, S., Wu, Y., Hou, Y., Guan, X., Castelvetere, M. P., Oblak, J. J., Banerjee, S., Filtz, T. M., Sarkar, F. H., Chen, X., et al. (2013) · Translational Oncology · doi:10.1593/tlo.13133 · Cited by 55
CXCR2 signaling regulates KRAS(G12D)-induced autocrine growth of pancreatic cancer
Purohit, A., Varney, M. L., Rachagani, S., Ouellette, M. M., Batra, S. K., & Singh, R. K. (2016) · Oncotarget · doi:10.18632/oncotarget.6906 · Cited by 43

Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
de Visser, K. E., & Joyce, J. A. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.016 · Cited by 4,059
Roles of the immune system in cancer: From tumor initiation to metastatic progression
Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
Veglia, F., Sanseviero, E., & Gabrilovich, D. I. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00490-y · Cited by 1,940
Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Han, F., Du, Y., Shi, H., & Zhou, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01332-8 · Cited by 1,612

See all 845

Authors: Steele, C. W., Karim, S. A., Leach, J. D. G., Bailey, P., Upstill-Goddard, R., Rishi, L., Foth, M., Bryson, S., McDaid, K., Wilson, Z., Eberlein, C., Candido, J. B., Clarke, M., Nixon, C., Connelly, J., Jamieson, N., Carter, C. R., Balkwill, F., Chang, D. K., Evans, T. R. J., Strathdee, D., Biankin, A. V., Nibbs, R. J. B., Barry, S. T., Sansom, O. J., & Morton, J. P.
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2016-06
Volume: 29
Issue: 6
Pages: 832-845
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccell.2016.04.014
OpenAlex: W2416038770
Cited by: 845
References: 66
FWCI: 31.37
Type: journal article
Language: en
Open access: hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks

Data sources